All companies
Visit website
Vymedic
OperatingVymedic Inc.
Healthcare · Founded 2020
Scientifically proven broad-spectrum antiviral beats industry-leading treatments in the suppression of flu, colds and common viruses.
Post-money valuation ⓘ
$20.2M
As of Mar 2021 · from Vymedic Stock 1 · pre-money + amount raised, not a traded price
Total raised
$202,470
Across 1 round since 2020
Latest share price
$5.00
Vymedic Stock 1 offering price
Financials
FY2018–FY2021 · from SEC filings · hover any figure for its source$0
−$46K
2018
$0
−$47K
2019
$0
−$208K
2020
$10K
−$296K
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019
FY2020
FY2021
Income statement
Revenue
$0
$0
$0
$10,349
Cost of goods sold
$0
$0
$0
$3,653
Gross margin
—
—
—
65%
Net income
-$45,688
-$46,788
-$208,331
-$295,575
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$3,105
$2,032
$6,411
$247,729
Accounts receivable
$0
$0
$0
$1,136
Total assets
$3,105
$2,032
$46,286
$752,595
Short-term debt
$0
$0
$0
$0
Long-term debt
$0
$0
$129,915
$1,103,070
Total liabilities
$0
$0
$129,915
$1,103,070
Other
Headcount
—
2
—
2
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$20.2M
post-money
Vymedic Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $202.5K / $1.1MPost-money $20.2M
Reg CF annual-report compliance
Possibly delinquent
Filed 1 of 6 annual reports (FY2020–FY2025)
Missing: 2020, 2022, 2023, 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 13 filings on EDGARSource: ManualCIK 0001824940Share price $5.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.